This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (28)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Psoriasis  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Association of Capillary Leak Syndrome With Apoptosis of Lesional Lymphocytes

Mariana J. Kaplan, MD; Charles N. Ellis, MD; Zsuzsanna Bata-Csorgo, MD; Ross S. Kaplan, MD; Judith L. Endres, BS; David A. Fox, MD

Arch Dermatol. 1999;135:553-557.

Background  Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation. After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus, lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.

Observations  A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%). Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.

Conclusions  Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome. These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators. Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.

From the Departments of Internal Medicine (Drs M. J. Kaplan and Fox and Ms Endres) and Dermatology (Drs Ellis and Bata-Csorgo), University of Michigan Medical School, Ann Arbor; and the Department of Dermatology (Dr R. S. Kaplan), University of California-Irvine.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 1999;135(5):617-618.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler et al.
NEJM 2008;358:140-151.
ABSTRACT | FULL TEXT  

Sirolimus-induced pneumonitis, sinusitis and macular oedema
Nayak et al.
Nephrol Dial Transplant 2004;19:2931-2931.
FULL TEXT  

Sirolimus-Associated Hepatotoxicity in Liver Transplantation
Neff et al.
The Annals of Pharmacotherapy 2004;38:1593-1596.
ABSTRACT | FULL TEXT